



ResApp Collaborates with Leading Humanitarian Organisation to Field Test ResApp's Smartphone-Based Pneumonia Diagnostic in the Developing World

Perth, Western Australia, 7 March 2016 -- ResApp Health Limited (ASX: RAP), announced today that it has signed a non-binding memorandum of understanding with a leading humanitarian organisation and UniQuest (the main commercialisation company of The University of Queensland), to enter into a partnership to field test ResApp's smartphone-based pneumonia diagnostic tool in the developing world.

Pneumonia is a disease that kills more than 950,000 children under five every year, the vast majority in South Asia and sub-Saharan Africa. Many of these deaths are caused by delays in diagnosis due to the lack of high quality medical care in these regions.

ResApp, UniQuest and the humanitarian organisation will work together to secure one or more field sites in the developing world. Subject to approval by local human research ethics committees, field sites are expected to be up-and-running in mid 2016.

Dr Tony Keating, CEO and Managing Director of ResApp said "We are very excited to collaborate with a global leader in the provision of health services throughout the developing world. Not only will we perform a field trial to gather additional clinical evidence, but we will also develop an in-depth understanding of the difficult environments in which their personnel operate and refine our application to suit."

- ENDS -

Contacts

Dr Tony Keating
CEO and Managing Director
+61 430 180 659
tony@resapphealth.com.au

Mr Brian Leedman
Executive Director
Vice President, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au

About ResApp Health Limited

ResApp Health Limited, founded in 2014, is developing smartphone medical applications for the diagnosis and management of respiratory disease. The



technology is based on machine learning algorithms that use sound alone to diagnose and measure the severity of respiratory conditions without the need for additional hardware. The algorithms were initially developed by The University of Queensland with funding from the Bill and Melinda Gates Foundation. ResApp has a multi-site clinical study underway and preliminary results demonstrated accurate diagnosis of pneumonia, asthma/viral wheeze, bronchiolitis, croup and upper respiratory tract infections in children. Approval has been recently received to extend the study to adults at two major Australian hospitals. Markets for ResApp's technology include telehealth use through partnerships with telehealth service providers, emergency department and regular clinic use by healthcare providers, at-home use by consumers and working with global aid and humanitarian organisations to deliver tools for the developing world.

For more information on ResApp, visit www.resapphealth.com.au.